| abstract |
FIELD: chemistry. n SUBSTANCE: described are heterobicyclic derivatives of formula (I) n , in which V denotes -C(R 7 )-; W denotes a single bond or -C(R 8 R 9 )-; X denotes O, S, SO, SO 2 or N(R 10 ); Y denotes -C(R 11 R 12 )-, -C(R 11 R 12 )C(R 13 R 14 )C(R 11 R 12 )C(R 13 R 14 )C(R 15 R 16 )-, -C(R 11 R 12 )C(R 13 R 14 )C(R 15 R 16 )C(R 17 R 18 )- or- C(R 11 )=C(R 12 )-; R 1 , R 2 , R 3 , R 4 and R 5 independently denote hydrogen, halogen, (lower)alkyl, fluoro(lower)alkyl, (lower)alkoxy group, fluoro(lower)alkoxy group, NH 2 -C(O); R 6 denotes a phenyl, pyridyl, pyrazolyl or thiazolyl group, where the group is optionally substituted with 1-4 substitutes selected from a group consisting of halogen, cyano group, (lower)alkyl, (lower)alkoxy group, COOH, 1H-tetrazol-5-yl, 5-oxo-4H-[1,2,4]oxadiazol-3-yl, where (lower)alkyl is optionally substituted with COOH. A pharmaceutical composition is also described. n EFFECT: said compounds inhibit L-CPT1 and can be used as medicinal agents. n 27 cl, 120 ex |